Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
Brandon W. Higgs(Parker Institute for Cancer Immunotherapy), Chris Morehouse, Laura K. Richman(University of Pennsylvania), Wendy I. White(University of North Carolina at Chapel Hill), David Fiorentino(Stanford University), Philip Z. Brohawn(Hofstra University), Bahija Jallal(Unknown), Steven A. Greenberg(Brigham and Women's Hospital), Zheng Liu(Wuhan University), Wei Zhu(Ministry of Education of the People's Republic of China), Peter A. Kiener(Institute of Neuroimmunology of the Slovak Academy of Sciences), Barbara White
Cited by 412
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.
|Proceedings of the National Academy of Sciences|1991|752
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|583
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|Cell|2020|546
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478